Navigation Links
Market Access Expert Firm, PRMA Consulting, Launches Companion Diagnostics Handbook
Date:5/16/2013

New York, NY (PRWEB) May 16, 2013

Leading UK company, PRMA Consulting launches PRMA Insights: Market Access Success for Companion Diagnostic–Drug Pairings in Oncology, a unique handbook that addresses the key issues that biopharmaceutical manufacturers should understand when developing new drug-test pairings.

Personalized medicine is gaining traction, particularly in oncology, with two recently approved drug–test pairings: Xalkori for ALK-positive NSCLC and Zelboraf for BRAF-mutation positive melanoma. Payors are willing to consider such high-price drugs in the context of small, clearly defined patient subpopulations. However, a largely unresolved issue is how the companion diagnostic testing is reimbursed; clearly, access to the drug risks being compromised if funding is not readily available.

Drug and diagnostics manufacturers must be familiar with the evidence requirements to support the drug and test as a pair, in order to ensure that clinical trials generate data that meets the expectations of both payors and regulators. Addressing these issues at the earliest stages allows manufacturers to develop a coherent and integrated market access strategy with realistic pricing expectations. This is clearly a major challenge for manufacturers, but there is little practical guidance available.

The new PRMA Insights handbook clearly addresses this by setting out payors’ attitudes to testing across the major markets, how tests are likely to be reimbursed, and realistic expectations of price points. It also offers practical recommendations to support strategy development for drug–test pairings.

David Sykes, founding partner of PRMA explains: “Many reports discuss the market opportunity for companion diagnostics but none considers the companion diagnostic and drug together, or offers practical advice on how to realize the market opportunity. Our handbook is packed full of strategic insights and recommendations.”

Examples of the issues covered in the handbook:

  •          What are the pricing and reimbursement mechanisms for the test? How are these connected, or disconnected, from the processes for the drug?
  •          What are realistic price expectations for the test within the different reimbursement frameworks?
  •          What evidence is needed for each element of the pairing?
  •          How should companion diagnostic testing be included in economic models?
  •          How is the clinical development program best designed to support both the drug and the test?
  •          How do manufacturers ensure that the requirement for a test does not become a barrier to prescription of the drug?    

PRMA will be available to discuss the Insights series at the upcoming ISPOR Conference in New Orleans, May 18-22, 2013, and in Chicago, June 1–3, 2013. Founding Partner, David Sykes and the handbook’s lead author, Dr. Clare Jones will be available for interviews. Both are available for phone interviews. http://www.prmaconsulting.com.

About PRMA Consulting: UK-headquartered PRMA Consulting specializes in pricing, reimbursement, and market access strategy; health economics and outcomes research; and licensing and due diligence.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10734820.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
5. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
6. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
7. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
8. GeneLink Marketing Efforts Poised to Show Results
9. Animal Biotechnology - Technologies, Markets and Companies
10. Gene Therapy - Technologies, Markets and Companies
11. Biomarkers - Technologies, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)...  VWR Corporation (NASDAQ: VWR), the leading global independent provider ... today reported its financial results for the fourth quarter and ... 4Q16 record quarterly net sales of $1.13 ... basis. 4Q16 EMEA-APAC segment net ... the Americas net sales increased 2.5%, or down 0.9% on ...
(Date:2/23/2017)... NEW YORK , Feb. 23, ... , a leading digital health company, and ... of telemedicine and remote patient monitoring, announce they ... reimbursements.  DN Telehealth maximizes collaboration ... real-time, extending consultations beyond a physical clinical setting ...
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook ... portfolio to include an array of biochemical analyses critical for Lead Discovery. ... their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of action, ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced today ... two key immunotherapy technologies from the University of ... a method to monitor a patient for response ... and CTLA-4.  The second license extends the technology ... is likely to have an immune-related adverse event ...
Breaking Biology Technology:
(Date:2/10/2017)... , Feb 10, 2017 ... new report "Personalized Medicine - Scientific and Commercial Aspects" ... ... personalized medicine. Diagnosis is integrated with therapy for selection of ... on early detection and prevention of disease in modern medicine. ...
(Date:2/8/2017)... YORK , Feb. 7, 2017 ... Driven largely by the confluence of organizations, desires ... distaste for knowledge-based systems (password and challenge questions), ... industrial, and government systems. The market is driven ... a demarcation between consumer and enterprise uses cases, ...
(Date:2/6/2017)... 6, 2017 According to Acuity Market ... border authorities to continue to embrace biometric and ... 2143 Automated Border Control (ABC) eGates and 1436 ... more than 163 ports of entry across the ... achieving a combined CAGR of 37%. APC Kiosks ...
Breaking Biology News(10 mins):